1652b0a3-dc1d-4490-9632-07673713deb1
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- COAGULATION+0.460
- ANGIOGENESIS+0.440
- MYOGENESIS+0.440
- APICAL_JUNCTION+0.360
- WNT_BETA_CATENIN_SIGNALING+0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.340
- NOTCH_SIGNALING+0.320
- XENOBIOTIC_METABOLISM+0.320
- APICAL_SURFACE+0.300
Top 10 suppressed
- E2F_TARGETS-0.540
- G2M_CHECKPOINT-0.510
- PROTEIN_SECRETION-0.480
- MYC_TARGETS_V1-0.440
- ANDROGEN_RESPONSE-0.290
- MYC_TARGETS_V2-0.270
- MTORC1_SIGNALING-0.240
- INTERFERON_ALPHA_RESPONSE-0.230
- MITOTIC_SPINDLE-0.220
- UNFOLDED_PROTEIN_RESPONSE-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d496ef4f-4716-4e6e-94e3-fce93b26d4ee | — | — | 0.975 |
| 2 | 57583139-d2d3-4b97-a616-aa96058d4682 | — | — | 0.910 |
| 3 | bb3dc2ff-a686-483e-8d3c-e06649462881 | — | — | 0.909 |
| 4 | 9b308588-5e79-46ab-b186-6edd686695c6 | — | — | 0.906 |
| 5 | 45b4921e-fce7-41f8-bb63-ed98343ceec8 | — | — | 0.901 |
| 6 | 80bea63b-bc3a-4999-8c11-a35c92183cd7 | — | — | 0.894 |
| 7 | SRR493947 | — | cohortA1 | 0.885 |
| 8 | MBCproject_0031_T1_RNA | — | A | 0.883 |
| 9 | 7645a3b1-639d-4677-8bcf-c16df24fcc2b | — | — | 0.880 |
| 10 | SAMN03290902 | — | — | 0.875 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| COAGULATION | 0.460 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.440 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.360 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.320 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.320 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.260 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.220 | Idelalisib | — uncovered |